J Korean Med Assoc.  2015 Jan;58(1):57-63. 10.5124/jkma.2015.58.1.57.

Pharmacologic treatment for inflammatory bowel disease

• Lee KJ

• KMID: 2149283
• DOI: http://doi.org/10.5124/jkma.2015.58.1.57

Abstract

Inflammatory bowel disease (IBD) is a rare condition characterized by chronic or relapsing immune activation and inflammation in the gastrointestinal tract. Crohn's disease and ulcerative colitis are the major forms of IBD. Although their etiology is not clear, these conditions are increasingly recognized in Korea. There is no curative treatment for Crohn's disease and ulcerative colitis. The primary goals of current therapy are to induce and maintain remission, which is closely associated with a patient's quality of life. Various drugs are used for diverse clinical presentations of IBD. International and Korean guidelines for the management of Crohn's disease and ulcerative colitis have been developed and published. This review describes pharmacologic treatment for Crohn's disease and ulcerative colitis primarily based on the recently published guidelines.

Keyword

Crohn disease; Inflammatory bowel diseases; Ulcerative colitis

MeSH Terms

Colitis, Ulcerative
Crohn Disease
Gastrointestinal Tract
Inflammation
Inflammatory Bowel Diseases*
Korea
Quality of Life

Reference

1. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007; 369:1627–1640.

2. Yang SK, Yun S, Kim JH, Park JY, Kim HY, Kim YH, Chang DK, Kim JS, Song IS, Park JB, Park ER, Kim KJ, Moon G, Yang SH. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study. Inflamm Bowel Dis. 2008; 14:542–549.

3. Kornbluth A, Sachar DB. Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010; 105:501–523.

4. Gisbert JP, Luna M, Gonzalez-Lama Y, Pousa ID, Velasco M, Moreno-Otero R, Mate J. Effect of 5-aminosalicylates on renal function in patients with inflammatory bowel disease: 4-year follow-up study. Gastroenterol Hepatol. 2008; 31:477–484.

5. Dubinsky MC. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol. 2004; 2:731–743.

6. Teml A, Schaeffeler E, Herrlinger KR, Klotz U, Schwab M. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet. 2007; 46:187–208.

7. Fraser AG. Methotrexate: first-line or second-line immunomodulator? Eur J Gastroenterol Hepatol. 2003; 15:225–231.

8. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003; 48:2122–2127.

9. Choi CH, Kim YH, Kim YS, Ye BD, Lee KM, Lee BI, Jung SA, Kim WH, Lee H. IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Guidelines for the mana-gement of ulcerative colitis. Intest Res. 2012; 10:1–25.

10. Dignass A, Eliakim R, Magro F, Maaser C, Chowers Y, Geboes K, Mantzaris G, Reinisch W, Colombel JF, Vermeire S, Travis S, Lindsay JO, Van Assche G. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012; 6:965–990.

11. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J. 1955; 2:1041–1048.

12. Travis SPL, Dinesen L. Remission in trials of ulcerative colitis: what does it mean? Pract Gastroenterol. 2006; 30:17–20.

13. Andus T, Kocjan A, Muser M, Baranovsky A, Mikhailova TL, Zvyagintseva TD, Dorofeyev AE, Lozynskyy YS, Cascorbi I, Stolte M, Vieth M, Dilger K, Mohrbacher R, Greinwald R. International Salofalk Suppository OD Study Group. Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. Inflamm Bowel Dis. 2010; 16:1947–1956.

14. Lamet M. A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg twice daily in patients with active mild-to-moderate ulcerative proctitis. Dig Dis Sci. 2011; 56:513–522.

15. Kruis W, Kiudelis G, Racz I, Gorelov IA, Pokrotnieks J, Horynski M, Batovsky M, Kykal J, Boehm S, Greinwald R, Mueller R. International Salofalk OD Study Group. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut. 2009; 58:233–240.

16. Bossa F, Fiorella S, Caruso N, Accadia L, Napolitano G, Valvano MR, Andriulli A, Annese V. Continuous infusion versus bolus administration of steroids in severe attacks of ulcerative colitis: a randomized, double-blind trial. Am J Gastroenterol. 2007; 102:601–608.

17. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006; (2):CD000544.

18. Ford AC, Achkar JP, Khan KJ, Kane SV, Talley NJ, Marshall JK, Moayyedi P. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2011; 106:601–616.

19. Fockens P, Mulder CJ, Tytgat GN, Blok P, Ferwerda J, Meuwissen SG, Tuynman HA, Dekker W, Gasthuis K, van Hees PA. Dutch Pentasa Study Group. Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Eur J Gastroenterol Hepatol. 1995; 7:1025–1030.

20. Travis SP, Stange EF, Lemann M, Oresland T, Chowers Y, Forbes A, D'Haens G, Kitis G, Cortot A, Prantera C, Marteau P, Colombel JF, Gionchetti P, Bouhnik Y, Tiret E, Kroesen J, Starlinger M, Mortensen NJ. European Crohn's and Colitis Organisation. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut. 2006; 55:Suppl 1. i16–i35.

21. Kim JH, Cheon JH, Kim WH. The frequency and the course of the adverse effects of azathioprine/6-mercaptopurine treatment in patients with inflammatory bowel disease. Korean J Gastroenterol. 2008; 51:291–297.

22. Dignass A, Van Assche G, Lindsay JO, Lemann M, Soderholm J, Colombel JF, Danese S, D'Hoore A, Gassull M, Gomollon F, Hommes DW, Michetti P, O'Morain C, Oresland T, Windsor A, Stange EF, Travis SP. European Crohn's and Colitis Organisation (ECCO). The second European evidence-based Consensus on the diagnosis and management of Crohn's dis-ease: current management. J Crohns Colitis. 2010; 4:28–62.

23. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976; 70:439–444.

24. Otley A, Steinhart AH. Budesonide for induction of remis-sion in Crohn's disease. Cochrane Database Syst Rev. 2005; (4):CD000296.

25. Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol. 2004; 2:379–388.

26. Prantera C, Cottone M, Pallone F, Annese V, Franze A, Cerutti R, Bianchi Porro G. Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial. Gastroenterology. 1999; 116:521–526.

27. D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A, Vermeire S, Van de Mierop FJ, Coche JC, van der Woude J, Ochsenkuhn T, van Bodegraven AA, Van Hootegem PP, Lambrecht GL, Mana F, Rutgeerts P, Feagan BG, Hommes D. Belgian Inflammatory Bowel Disease Research Group. North-Holland Gut Club. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008; 371:660–667.

28. Regueiro M, Schraut W, Baidoo L, Kip KE, Sepulveda AR, Pesci M, Harrison J, Plevy SE. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology. 2009; 136:441–450.

29. Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease. Cochrane Database Syst Rev. 2005; (1):CD003715.